Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Journal of Molecular and Cellular Cardiology
|
April 15, 2004
Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho
Randa Hilal-Dandan, Christopher K Means, Asa B Gustafsson, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 18, 2011
Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
Tong Zhang, Zhuangjie Li, Huong Dang, et al.
The Journal of Biological Chemistry
|
August 6, 2003
Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion
Amy L Howes, Jane F Arthur, Tong Zhang, et al.
Clinical Pharmacology in Drug Development
|
February 12, 2024
Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
Caroline A Lee, Stefan Schreiber, Brian Bressler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2013
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer
Alberto Chiappori, Charles Williams, Donald W Northfelt, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
June 10, 2008
Myocardial expression, signaling, and function of GPR22: a protective role for an orphan G protein-coupled receptor
John W Adams, Jianming Wang, James R Davis, et al.
European Journal of Pharmacology
|
March 25, 2008
Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist
John W Adams, Juan Ramirez, Danny Ortuno, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology
John W Adams, Juan Ramirez, Yunqing Shi, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents
Peter I Dosa, Sonja Strah-Pleynet, Honnappa Jayakumar, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 11, 2015
Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat
Thuy-Anh Tran, Young-Jun Shin, Bryan Kramer, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Journal of Molecular and Cellular Cardiology
|
April 15, 2004
Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho
Randa Hilal-Dandan, Christopher K Means, Asa B Gustafsson, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
October 18, 2011
Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection
Tong Zhang, Zhuangjie Li, Huong Dang, et al.
The Journal of Biological Chemistry
|
August 6, 2003
Akt-mediated cardiomyocyte survival pathways are compromised by G alpha q-induced phosphoinositide 4,5-bisphosphate depletion
Amy L Howes, Jane F Arthur, Tong Zhang, et al.
Clinical Pharmacology in Drug Development
|
February 12, 2024
Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults
Caroline A Lee, Stefan Schreiber, Brian Bressler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 19, 2013
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer
Alberto Chiappori, Charles Williams, Donald W Northfelt, et al.
American Journal of Physiology. Heart and Circulatory Physiology
|
June 10, 2008
Myocardial expression, signaling, and function of GPR22: a protective role for an orphan G protein-coupled receptor
John W Adams, Jianming Wang, James R Davis, et al.
European Journal of Pharmacology
|
March 25, 2008
Anti-thrombotic and vascular effects of AR246686, a novel 5-HT2A receptor antagonist
John W Adams, Juan Ramirez, Danny Ortuno, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 25, 2009
APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology
John W Adams, Juan Ramirez, Yunqing Shi, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 12, 2009
Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents
Peter I Dosa, Sonja Strah-Pleynet, Honnappa Jayakumar, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 11, 2015
Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat
Thuy-Anh Tran, Young-Jun Shin, Bryan Kramer, et al.
Page
of 3